Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
2.5 Market Structure
3 Research Methodology
3.1.1 Primary Research Methodology
3.1.2 Secondary Research Methodology
3.1.3 Market Share Analysis
3.1.4 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing prevalence of diabetes and atherosclerosis (Impact Weightage 40%)
4.2.2 Change in lifestyle (Impact Weightage 35%)
4.2.3 Increasing prevalence of glaucoma, lymphoma, and multiple myeloma (Impact Weightage 25%)
4.3 Restraints
4.3.1 Side effect of treatment (Impact Weightage 60%)
4.3.2 High cost of treatment (Impact Weightage 40%)
5 Market Factor Analysis
5.1 Porters Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 R&D
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-sales Monitoring
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
6 Global Retinal Vein Occlusion Market, By Type
6.1 Branch Retinal Artery Occlusion
6.2 Central Retinal Vein Occlusion
7 Global Retinal Vein Occlusion Market, By Condition
7.1 Non-Ischemic
7.2 Ischemic
8 Global Retinal Vein Occlusion Market, By Diagnosis
8.1 Optical Coherence Tomography
8.2 Fundoscopic Examination
8.3 Fluorescein Angiography
9 Global Retinal Vein Occlusion Market, By Treatment
9.1 Antivascular Endothelial Growth Factor
9.1.1 Aflibercept
9.1.2 Ranibizumab
9.2 Corticosteroid Drugs
9.2.1 Triamcinolone Acetonide
9.2.2 Dexamethasone
9.3 Laser Retinal Photocoagulation
10 Global Retinal Vein Occlusion Market, By End User
10.1 Hospitals and Clinics
10.2 Research & Academics Centers
11 Global Retinal Vein Occlusion Market, By Region
11.1 Americas
11.1.1 North America
11.1.1.1 U. S.
11.1.1.2 Canada
11.1.2 South America
11.2 Europe
11.2.1 Western Europe
11.2.1.1 Germany
11.2.1.2 France
11.2.1.3 U.K
11.2.1.4 Italy
11.2.1.5 Spain
11.2.1.6 Rest of Western Europe
11.2.2 Eastern Europe
11.3 Asia Pacific
11.3.1 Japan
11.3.2 China
11.3.3 India
11.3.4 Australia
11.3.5 Republic of Korea
11.3.6 Rest of Asia Pacific
11.4 Middle East & Africa
11.4.1 Africa
12 Competitive Landscape
12.1 Introduction
12.2 Company Share Analysis
13 Company Profiles
13.1 Allergan Plc
13.1.1 Company Overview
13.1.2 Financials
13.1.3 Products
13.1.4 Strategy
13.1.5 Key Developments
13.2 Bayer
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Products
13.2.4 Strategy
13.2.5 Key Developments
13.3 Bristol-Myers Squibb
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Products
13.3.4 Strategy
13.3.5 Key Developments
13.4 Ellex Medical Lasers Ltd.
13.4.1 Company Overview
13.4.2 Financials
13.4.3 Products
13.4.4 Strategy
13.4.5 Key Developments
?
13.5 GlaxoSmithKline plc
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Products
13.5.4 Strategy
13.5.5 Key Developments
13.6 IRIDEX Corporation
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Products
13.6.4 Strategy
13.6.5 Key Developments
13.7 Lumenis
13.7.1 Company Overview
13.7.2 Financials
13.7.3 Products
13.7.4 Strategy
13.7.5 Key Developments
13.8 Novartis
13.8.1 Company Overview
13.8.2 Financials
13.8.3 Products
13.8.4 Strategy
13.8.5 Key Developments
13.9 NIDEK CO.,LTD.
13.9.1 Company Overview
13.9.2 Financials
13.9.3 Products
13.9.4 Strategy
13.9.5 Key Developments
13.1 Regeneron Pharmaceuticals
13.10.1 Company Overview
13.10.2 Financials
13.10.3 Products
13.10.4 Strategy
13.10.5 Key Developments
13.11 F. Hoffmann-La Roche AG
13.11.1 Company Overview
13.11.2 Financials
13.11.3 Products
13.11.4 Strategy
13.11.5 Key Developments
?
13.12 Quantel Medical Inc
13.12.1 Company Overview
13.12.2 Financials
13.12.3 Products
13.12.4 Strategy
13.12.5 Key Developments
13.13 Topcon Medical Systems, Inc.
13.13.1 Company Overview
13.13.2 Financials
13.13.3 Products
13.13.4 Strategy
13.13.5 Key Developments
13.14 ZEISS
13.14.1 Company Overview
13.14.2 Financials
13.14.3 Products
13.14.4 Strategy
13.14.5 Key Developments
14 MRFR Conclusion
14.1 Key Findings
14.1.1 From CEO's View Point
14.1.2 Unmet Needs
14.2 Key companies to watch
15 Appendix
15.1 Discussion Blue Print